Published in Bacteriol Rev on September 01, 1966
Tularemia. Clin Microbiol Rev (2002) 8.51
A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun (2005) 2.53
Detection of Francisella tularensis in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochromatographic handheld assay, and a PCR. Clin Diagn Lab Immunol (2000) 1.67
Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development. Microbiol Mol Biol Rev (2009) 1.59
Identification of an essential Francisella tularensis subsp. tularensis virulence factor. Infect Immun (2008) 1.50
Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect Immun (2006) 1.50
A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS One (2008) 1.39
Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection. Infect Immun (1975) 1.37
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine (2008) 1.35
Treatment of influenza infection of mice by using rimantadine hydrochlorides by the aerosol and intraperitoneal routes. Antimicrob Agents Chemother (1975) 1.34
Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun (2008) 1.31
Experimental tularemia in Macaca mulatta: relationship of aerosol particle size to the infectivity of airborne Pasteurella tularensis. Infect Immun (1972) 1.27
Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun (2006) 1.27
Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine (2007) 1.24
Continuous aerosol therapy system using a modified Collison nebulizer. J Clin Microbiol (1977) 1.23
Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis. Infect Immun (2009) 1.22
Pathogenesis of tularemia in monkeys aerogenically exposed to Francisella tularensis 425. Infect Immun (1972) 1.18
Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One (2010) 1.13
Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol (2009) 1.12
Development of vaccines against burkholderia pseudomallei. Front Microbiol (2011) 1.10
Several membrane polypeptides of the live vaccine strain Francisella tularensis LVS stimulate T cells from naturally infected individuals. J Clin Microbiol (1990) 1.08
The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J Clin Invest (1969) 1.05
Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling. J Leukoc Biol (2009) 1.05
Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine (2009) 1.03
Cell-mediated and humoral immune responses induced by scarification vaccination of human volunteers with a new lot of the live vaccine strain of Francisella tularensis. J Clin Microbiol (1992) 1.02
Antibodies for biodefense. MAbs (2011) 1.02
Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine (2009) 1.01
Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains. Vaccine (2009) 0.98
Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine (2009) 0.97
Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine (2009) 0.96
T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria. Infect Immun (2009) 0.94
Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect Immun (2010) 0.93
Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS). PLoS One (2010) 0.92
Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J Leukoc Biol (2011) 0.92
Vaccines against tularemia. Hum Vaccin (2009) 0.91
A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia. PLoS One (2013) 0.89
Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia. Clin Vaccine Immunol (2008) 0.89
Rationally designed tularemia vaccines. Expert Rev Vaccines (2009) 0.87
Members of the Francisella tularensis phagosomal transporter subfamily of major facilitator superfamily transporters are critical for pathogenesis. Infect Immun (2012) 0.86
Live attenuated tularemia vaccines: recent developments and future goals. Vaccine (2013) 0.86
Pneumonic tularemia in rabbits resembles the human disease as illustrated by radiographic and hematological changes after infection. PLoS One (2011) 0.86
Identification of a live attenuated vaccine candidate for tularemia prophylaxis. PLoS One (2013) 0.85
Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. PLoS Pathog (2014) 0.83
Immunoproteomic analysis of the human antibody response to natural tularemia infection with Type A or Type B strains or LVS vaccination. Int J Med Microbiol (2011) 0.82
A Francisella tularensis live vaccine strain that improves stimulation of antigen-presenting cells does not enhance vaccine efficacy. PLoS One (2012) 0.82
Modeling inhalational tularemia: deliberate release and public health response. Biosecur Bioterror (2011) 0.81
Tularemia vaccine development: paralysis or progress? Vaccine (Auckl) (2016) 0.81
Identification of Francisella novicida mutants that fail to induce prostaglandin E(2) synthesis by infected macrophages. Front Microbiol (2013) 0.80
Francisella tularensis Vaccines Elicit Concurrent Protective T- and B-Cell Immune Responses in BALB/cByJ Mice. PLoS One (2015) 0.80
Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clin Vaccine Immunol (2009) 0.79
Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain. Infect Immun (2014) 0.79
TolC-dependent modulation of host cell death by the Francisella tularensis live vaccine strain. Infect Immun (2014) 0.79
Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates. Pathog Dis (2015) 0.78
A dose and time response Markov model for the in-host dynamics of infection with intracellular bacteria following inhalation: with application to Francisella tularensis. J R Soc Interface (2014) 0.78
Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain. Clin Vaccine Immunol (2013) 0.77
Preclinical testing of a vaccine candidate against tularemia. PLoS One (2015) 0.77
Identification of mechanisms for attenuation of the FSC043 mutant of Francisella tularensis SCHU S4. Infect Immun (2014) 0.75
The Natural History of Pneumonic Tularemia in Female Fischer 344 Rats after Inhalational Exposure to Aerosolized Francisella tularensis Subspecies tularensis Strain SCHU S4. Am J Pathol (2016) 0.75
The route less taken: pulmonary models of enteric Gram-negative infection. Pathog Dis (2013) 0.75
Respiratory antibody to Francisella tularensis in man. Bacteriol Rev (1966) 0.75
Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol (1961) 7.52
Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med (1961) 5.12
Studies on the variation of Bacterium tularense. J Bacteriol (1951) 4.46
AEROSOL INFECTION OF MAN WITH PASTEURELLA TULARENSIS. Bacteriol Rev (1961) 3.62
Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol Rev (1962) 2.19
Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proc Soc Exp Biol Med (1961) 1.92
A MOBILE LABORATORY UNIT FOR EXPOSURE OF ANIMALS AND HUMAN VOLUNTEERS TO BACTERIAL AND VIRAL AEROSOLS. Am Rev Respir Dis (1964) 1.89
Immunological aspects of airborne infection: reactions to inhaled antigens. Bacteriol Rev (1961) 1.72
LIVE TULAREMIA VACCINE I. : Host-Parasite Relationship in Monkeys Vaccinated Intracutaneously or Aerogenically. J Bacteriol (1962) 1.61
SIMULTANEOUS AEROSOL IMMUNIZATION OF MONKEYS WITH LIVE TULAREMIA AND LIVE VENEZUELAN EQUINE ENCEPHALOMYELITIS VACCINES. Mil Med (1964) 1.48
Airborne immunization against tuberculosis. Science (1958) 1.13
Distemper Immunization of Ferrets by Nebulization with Egg Adapted Virus. Science (1954) 1.13
Distemper immunization of mink by air-borne infection with egg-adapted virus. J Am Vet Med Assoc (1954) 1.12
Armed Forces Epidemiological Board activities of the Commission on Epidemiological Survey, 1961. Mil Med (1962) 0.93
[Comparative effectiveness of nasal and cutaneous vaccination against tularemia in experimental conditions]. Zh Mikrobiol Epidemiol Immunobiol (1954) 0.89
Pathogenesis of Escherichia coli diarrhea. N Engl J Med (1971) 10.36
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis (1974) 6.38
Typhoid fever: pathogenesis and immunologic control. N Engl J Med (1970) 4.95
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Fecal leukocytes in diarrheal illness. Ann Intern Med (1972) 3.89
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis (1974) 2.73
Suppressive activity of mefloquine in sporozoite-induced human malaria. Antimicrob Agents Chemother (1976) 2.71
Typhoid fever: pathogenesis and immunologic control. 2. N Engl J Med (1970) 2.63
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Adverse effect of lomotil therapy in shigellosis. JAMA (1973) 2.57
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Immunity to enterotoxigenic Escherichia coli. Infect Immun (1979) 2.30
Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis (1972) 2.29
Invasive Escherichia coli. J Infect Dis (1978) 2.19
Influenza antibody in human respiratory secretions after subcutaneous or respiratory immunization with inactivated virus. Nature (1968) 2.10
Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1974) 2.08
The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bull N Y Acad Med (1971) 2.07
Histopathology of the upper small intestines in typhoid fever. Biopsy study of experimental disease in man. Am J Dig Dis (1966) 1.97
The response of man to virulent Shigella flexneri 2a. J Infect Dis (1969) 1.97
Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. JAMA (1968) 1.93
Antibody responses in nasal secretions and serum of elderly persons following local or parenteral administration of inactivated influenza virus vaccine. J Immunol (1969) 1.91
Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci (1973) 1.84
Immunity in typhoid fever: evaluation of live streptomycin-dependent vaccine. Antimicrob Agents Chemother (Bethesda) (1970) 1.82
Treatment of falciparum malaria caused by strain resistant to quinine. JAMA (1970) 1.81
Clinical approach to infectious diarrheas. Medicine (Baltimore) (1973) 1.75
Cutaneous responses to cholera skin toxin in man. I. Responses in unimmunized American males. J Infect Dis (1972) 1.74
BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1975) 1.61
Lack of enhanced oxygen consumption by polymorphonuclear leukocytes on phagocytosis of virulent Salmonella typhi. Science (1972) 1.44
Genetic susceptibility to cholera. Ann Hum Biol (1980) 1.44
Pathogenesis of shigella diarrhea. Serum anticytotoxin antibody response produced by toxigenic and nontoxigenic Shigella dysenteriae 1. J Clin Invest (1976) 1.43
Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am J Epidemiol (1969) 1.42
Peptic ulcer disease: a bacterial infection? N Engl J Med (1987) 1.41
Rocky Mountain spotted fever: a comparative study of the active immunity induced by inactivated and viable pathogenic Rickettsia rickettsii. J Infect Dis (1973) 1.39
Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis (1972) 1.39
Murine model for study of cell-mediated immunity: protection against death from fully virulent Francisella tularensis infection. Infect Immun (1975) 1.37
Efficacy of a live oral cholera vaccine in human volunteers. Dev Biol Stand (1976) 1.37
Q fever hepatitis. Ann Intern Med (1971) 1.34
The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity. Ann Intern Med (1974) 1.33
Long-term Shigella-carrier state. N Engl J Med (1973) 1.32
Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc Soc Exp Biol Med (1969) 1.29
Sources of contamination in open heart surgery. JAMA (1974) 1.29
Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am Rev Respir Dis (1980) 1.26
An endogenous mediator of depression of amino acids and trace metals in serum during typhoid fever. J Infect Dis (1972) 1.26
Evaluation of amantadine hydrochloride in the treatment of A2 influenzal disease. Bull World Health Organ (1969) 1.26
Comparison of trimethoprim-sulfamethoxazole and amoxicillin in therapy of chloramphenicol-resistant and chloramphenicol-sensitive typhoid fever. J Infect Dis (1975) 1.24
Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. J Infect Dis (1977) 1.22
Antimalarial effects of tetracyclines in man. J Trop Med Hyg (1971) 1.19
Live oral cholera vaccine: evaluation of the clinical effectiveness of two strains in humans. Infect Immun (1974) 1.18
Pathogenesis of tularemia in monkeys aerogenically exposed to Francisella tularensis 425. Infect Immun (1972) 1.18
Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines. Am J Epidemiol (1972) 1.18
Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis. Infect Immun (1975) 1.16
Recent studies on live tularemia vaccine. Med Ann Dist Columbia (1967) 1.15
Attenuated, streptomycin-dependent Salmonella typhi oral vaccine: potential deleterious effects of lyophilization. J Infect Dis (1976) 1.15
On the demonstration of circulating human endogenous pyrogen. Proc Soc Exp Biol Med (1972) 1.14
Effect of aerosol age on the infectivity of airborne Pasteurella tularensis for Macaca mulatta and man. J Bacteriol (1966) 1.14
Typhoid fever vaccine--yes or no? Med Clin North Am (1967) 1.14
Mucociliary function during experimentally induced rhinovirus infection in man. Ann Otol Rhinol Laryngol (1973) 1.13
Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. JAMA (1970) 1.12
Appraisal of typhoid vaccine in experimentally infected human subjects. Trans Am Clin Climatol Assoc (1967) 1.10
Comparative efficacy of chloramphenicol, ampicillin, and co-trimoxazole in the treatment of typhoid fever. Lancet (1976) 1.09
Detection of a leukocytic endogenous mediator-like mediator of serum amino acid and zinc depression during various infectious illnesses. Infect Immun (1975) 1.09
Cholera, non-vibrio cholera, and stomach acid. Lancet (1978) 1.07
Studies of immunity in typhoid fever. Protection induced by killed oral antigens or by primary infection. Bull World Health Organ (1971) 1.06
Analysis of infections acquired by the severely injured patient. Surg Gynecol Obstet (1973) 1.06
The problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera. Trans R Soc Trop Med Hyg (1979) 1.06
Cannabis, hypochlorhydria, and cholera. Lancet (1978) 1.05
Infection in the severely traumatized patient. Ann Surg (1974) 1.05
The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J Clin Invest (1969) 1.05
Lactulose therapy in Shigella carrier state and acute dysentery. Antimicrob Agents Chemother (1975) 1.04
Low-Temperature-Adapted Influenza A2/AA/6/60 Virus Vaccine in Man. Infect Immun (1973) 1.03
Oral tularemia vaccine in man. Antimicrob Agents Chemother (Bethesda) (1966) 1.03
Host-parasite relationship in monkeys administered live tularemia vaccine. Am J Pathol (1970) 1.03
Alice strain live attenuated influenza (H3N2) vaccin in an elderly population. Am J Epidemiol (1975) 1.02
Diarrheal diseases. Dis Mon (1969) 1.00
Duodenal isolation of Salmonella typhi by string capsule in acute typhoid fever. J Clin Microbiol (1976) 0.99
Selective primary health care: strategies for control of disease in the developing world. XX. Typhoid fever. Rev Infect Dis (1985) 0.99
Failure of a 3-substituted triazinoindole in the prevention of experimental human rhinovirus infection. Chemotherapy (1973) 0.98
Tularemia epidemic--Vermont, 1968. N Engl J Med (1969) 0.98
Immunization against typhoid fever. Annu Rev Med (1979) 0.98
On the pathogenesis of typhoid fever. Arch Intern Med (1978) 0.98
Study of induced typhoid fever in man. I. Evaluation of vaccine effectiveness. Trans Assoc Am Physicians (1966) 0.96
Infecting dose and severity of typhoid: analysis of volunteer data and examination of the influence of the definition of illness used. Epidemiol Infect (1995) 0.95
Tryptophan metabolism during infectious illness in man. J Infect Dis (1970) 0.95
Whole-blood amino acids in experimentally induced typhoid fever in man. N Engl J Med (1968) 0.94
Reactogenicity and immunogenicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults. J Infect Dis (1977) 0.94
Enterotoxic diarrheal syndromes. Annu Rev Med (1973) 0.93
Specific microbial infections of the myocardium and pericardium. A study of 82 patients. Arch Intern Med (1967) 0.92
Cellular inflammatory responses of man to bacterial endotoxin: a comparison with PPD and other bacterial antigens. J Immunol (1972) 0.92
The nature of endotoxin tolerance. Trans Am Clin Climatol Assoc (1975) 0.89